SPECT/CT in Endocrine and Neuroendocrine Tumors
The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors
1 other identifier
interventional
200
1 country
1
Brief Summary
The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management: Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up. It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2002
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2002
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 29, 2005
CompletedFirst Posted
Study publicly available on registry
September 30, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2006
CompletedOctober 15, 2008
September 1, 2005
2 years
September 29, 2005
October 11, 2008
Conditions
Outcome Measures
Primary Outcomes (1)
The impact of imaging modality on patient management
Secondary Outcomes (1)
The impact of imaging modality on patient management
Interventions
Eligibility Criteria
You may qualify if:
- Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors.
- Patient signed informed consent
You may not qualify if:
- The study will not be performed in pregnant or lactating women.
- Patient will not be able or willing to tolerate the scan until its completion.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rambam Medical Center
Haifa, Israel
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zohar Keidar, MD,PhD
Rambam Health Care Campus
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 29, 2005
First Posted
September 30, 2005
Study Start
January 1, 2002
Primary Completion
January 1, 2004
Study Completion
January 1, 2006
Last Updated
October 15, 2008
Record last verified: 2005-09